AstraZeneca has finalised a previously announced $520 million payout to settle federal government allegations that it marketed its antipsychotic Seroquel (quetiapine fumarate) for unapproved uses1. The company has resolved civil allegations brought by the Department of Justice under the US False Claims Act and will not face criminal charges
...
Please login to read the full article.
